Articles By Marcus Johnson

  1. HIV Drug Tabbed With Prevention Of Cervical Cancer 2/19/2014

    The HIV drug lopinavir has been studied by researchers looking for its effects on certain cancers. A University of Manchester study found that lopinavir was extremely successful at fighting cervical cancer—the drug killed HPV, or the pre-cancerous cells, in about 90%of women. Unlike other cancer treatments, lopinavir was not found to have any side effects. Photos of patients at the end of the study showed a reduction in the size of cervical lesions.

  2. Digoxin Could Significantly Lower Risk Of Prostate Cancer 2/13/2014

    Digoxin is a widely used drug in Great Britain that costs about one pound per month for end users. It is currently used to treat patients with heart issues, particularly heart failure and abnormal heart rhythms.

  3. FDA Needs More Information On Sprout's Female “Viagra” Drug 2/12/2014

    The FDA wants more information from Sprout Pharmaceuticals on their female “Viagra” drug, flibanserin. Sprout acquired the drug from Boehringer Ingelheim in 2011, and has since worked to develop it into a suitable option for women in western markets

  4. Survey Shows Half Of Drug Companies Use Counter-Generics Teams 2/11/2014

    A study done by Cutting Edge Information indicated that a significant portion of pharmaceutical companies use counter-generics teams to protect their drugs’ revenue streams, even as their patents expire. Some pharmaceutical companies have entire divisions dedicated to counter-generics, while others only create or employ a team when a particular drug’s patent is set to expire.

  5. Johnson & Johnson's Agreement With Yale Expected To Benefit Industry 2/7/2014

    Johnson & Johnson’s partnership with the Yale University School of Medicine will provide Yale with access to de-identified information from clinical studies that the pharamaceutical company has already completed. Johnson & Johnson’s new agreement will help improve the industry’s research and could possibly serve as a model for other pharmaceutuical companies to follow.

  6. Can JAK Inhibitors Treat Stomach And Colorectal Cancers? 2/7/2014

    A class of drugs called JAK inhibitors are currenting being used as a treatment for myelofibrosis, a condition that mimics cancer in a number of ways. Researchers are determining if JAK inhibitors can be used to treat stomach and colorectal cancers as well as other diseases such as lupus and rheumatoid arthritis.

  7. Pfizer's Breast Cancer Drug Trial Deemed A Success 2/4/2014

    Pharmaceutical giant Pfizer has produced a new breast cancer drug which has generated successful results in clinical trial. The drug’s name is Palbociclib, and the company has invested heavily in its development. Pfizer estimates that the drug could net about $5 billion each year once in production.

  8. FDA Expected To Address Off-Label Marketing 2/4/2014

    The FDA is expected to address the practice of pharmaceutical companies making off-label claims about their products. Pharmaceutical companies cannot legally make off-label claims and are required to fully disclose any side-effects in any advertisements. While doctors can prescribe drugs for a number of different uses, drug companies can only market drugs for uses approved by the FDA.

  9. FDA Reassessing Testosterone Product Safety 2/4/2014

    Products marketed at middle aged western men looking to increase their energy levels, strength, and libidos have surged in recent years. Many of these products include testosterone therapy. Since 2010, there have been multiple studies on testosterone treatment, and there have been enough negative effects to prompt the FDA to start the reassessment process on drugs that use testosterone.

  10. Geisinger and Regeneron Partner Up 2/4/2014

    In an effort to spur innovation and improve care for patients, Geisinger Health System and Regeneron Pharmaceuticals announced that the two companies would collaborate on research in order to help find the genetic components of diseases in humans.